The detection of metabolic dysfunction-associated fatty liver disease among new recruits in Tianjin and the effect of recruit training on the prognosis

doi:10.11958/20252745

Abstract

Abstract:

Objective To explore metabolic dysfunction-associated fatty liver disease (MAFLD) among new recruits and the effect of recruit training on the outcome of MAFLD. Methods A total of 3 469 new recruits were selected for the spring re-examination in Tianjin in 2024. Baseline data and MAFLD status of new recruits were collected. MAFLD recruits from one training unit were selected and divided into the MAFLD-resolved group and the non-resolved group based on post-training assessment. Changes in general characteristics, body composition, laboratory parameters and transient elastography parameters before and after training were compared. Results Among the reexamined recruits, 215 cases (6.2%) were diagnosed with MAFLD. Recruits with MAFLD exhibited higher body weight, body mass index (BMI) and a greater proportion of overweight/obesity compared to those recruits without MAFLD. Of the 56 selected MAFLD recruits, 36 cases (64.3%) returned to normal after recruit training. After recruit training, body weight, BMI, waist circumference, waist to hip ratio, body fat, body fat percentage, fasting blood glucose (FPG), alanine aminotransferase (ALT), aspartate aminotransferase (AST), uric acid (UA), liver steatosis analysis value and liver stiffness decreased compared to these indicators before the recruit training (P<0.05), while hip circumference, blood urea nitrogen (BUN) and triglyceride (TG) increased conversely (P<0.05). After training, the non-resolved group demonstrated higher gamma-glutamyl transferase (GGT) and liver steatosis analysis value than those of the resolved group (P<0.05), with no statistically significant differences observed in other indicators between the groups (P>0.05). Conclusion Recruit training can help MAFLD return to normal.

Key words: metabolic dysfunction-associated fatty liver disease, body weight, exercise, new recruit, outcome

CLC Number:

R575.5，R875

Figures/Tables 3

References 18

[1]	范建高, 徐小元, 南月敏, 等. 代谢相关(非酒精性)脂肪性肝病防治指南(2024年版)[J]. 实用肝脏病杂志, 2024, 27(4):494-510.
	FAN J G, XU X Y, NAN Y M, et al. Guidelines for the prevention and treatment of metabolic dysfunction-associated(non-alcoholic) fatty liver disease(Version 2024)[J]. Journal of Practical Hepatology, 2024, 27(4):494-510. doi:2010.3760/cma.j.cn501113-20240327-20200163.
[2]	GOFTON C, UPENDRAN Y, ZHENG M-H, et al. MAFLD:How is it different from NAFLD?[J]. Clin Mol Hepatol, 2023, 29(Suppl):S17-S31. doi:10.3350/cmh.2022.0367.
[3]	GOLABI P, OWRANGI S, YOUNOSSI Z M. Global perspective on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis - prevalence,clinical impact,economic implications and management strategies[J]. Aliment Pharmacol Ther, 2024,59 Suppl 1:S1-S9. doi:10.1111/apt.17833.
[4]	ZHOU F, ZHOU J H, WANG W X, et al. Unexpected rapid Increase in the burden of NAFLD in China From 2008 to 2018:a systematic review and meta-analysis[J]. Hepatology, 2019, 70(4):1119-1133. doi:10.1002/hep.30702.
[5]	RINELLA M E, NEUSCHWANDER-TETRI B A, SIDDIQUI M S, et al. AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease[J]. Hepatology, 2023, 77(5):1797-1835. doi:10.1097/hep.0000000000000323.
[6]	CHEN Y G, YANG C W, CHUNG C H, et al. The association between metabolic risk factors,nonalcoholic fatty liver disease,and the incidence of liver cancer:a nationwide population-based cohort study[J]. Hepatol Int, 2022, 16(4):807-816. doi:10.1007/s12072-021-10281-9.
[7]	HUANG D Q, EL-SERAG H B, LOOMBA R. Global epidemiology of NAFLD-related HCC:trends,predictions,risk factors and prevention[J]. Nat Rev Gastroenterol Hepatol, 2021, 18(4):223-238. doi:10.1038/s41575-020-00381-6.
[8]	中华人民共和国国家卫生健康委员会医政司. 肥胖症中国诊疗指南(2024年版)[J]. 协和医学杂志, 2025, 16(1):90-108.
	Department of Medical Administration,National Health Commission of the People's Republic of China. Chinese guidelines for the clinical management of obesity(2024 Edition)[J]. Medical Journal of Peking Union Medical College Hospital, 2025, 16(1):90-108. doi:2010.12290/xhyxzz.12024-10918.
[9]	NASH E, LIU K. Exercise in the management of metabolic dysfunction-associated fatty liver disease—is more the answer,or is it just one piece of the puzzle?[J]. Hepatobiliary Surg Nutr, 2024, 13(2):329-332. doi:10.21037/hbsn-23-686.
[10]	ALI S M J, LAI M. Metabolic dysfunction-associated steatotic liver disease[J]. Ann Intern Med, 2025, 178(1):ITC1-ITC16. doi:10.7326/annals-24-02933.
[11]	PAPAKONSTANTINOU E, OIKONOMOU C, NYCHAS G, et al. Effects of diet,lifestyle,chrononutrition and alternative dietary interventions on postprandial glycemia and insulin resistance[J]. Nutrients, 2022, 14(4):823. doi:10.3390/nu14040823.
[12]	KEATING S E, CHAWLA Y, DE A, et al. Lifestyle intervention for metabolic dysfunction-associated fatty liver disease:a 24-h integrated behavior perspective[J]. Hepatol Int, 2024, 18(S2):959-976. doi:10.1007/s12072-024-10663-9.
[13]	KEATING S E, SABAG A, HALLSWORTH K, et al. Exercise in the management of metabolic-associated fatty liver disease (MAFLD) in adults:a position statement from exercise and sport science Australia[J]. Sports Med, 2023, 53(12):2347-2371. doi:10.1007/s40279-023-01918-w.
[14]	ZHANG Y, WEI Y, LIU H, et al. Protective effect of exercise on metabolic dysfunction‑associated fatty liver disease:Potential epigenetic mechanisms (Review)[J]. Int J Mol Med, 2025, 56(4):146. doi:10.3892/ijmm.2025.5587.
[15]	HAUFE S, HUPA-BREIER K L, BAYERLE P, et al. Telemonitoring-supported exercise training in employees with metabolic syndrome improves liver inflammation and fibrosis[J]. Clin Transl Gastroenterol, 2021, 12(6):e00371. doi:10.14309/ctg.0000000000000371.
[16]	ZHANG Y, WEI Q, GENG X, et al. Long-term aerobic exercise enhances hepatoprotection in MAFLD by modulating exosomal miR-324 via ROCK1[J]. Metabolites, 2024, 14(12):692. doi:10.3390/metabo14120692.
[17]	BRASCHLER L, NIKOLAIDIS P T, THUANY M, et al. Physiology and pathophysiology of marathon running:a narrative review[J]. Sports Med Open, 2025, 11(1):10. doi:10.1186/s40798-025-00810-3.
[18]	LEIT O L, MAROCOLO M, DE SOUZA H L R, et al. Multicomponent exercise program for improvement of functional capacity and lipidic profile of older women with high cholesterol and high triglycerides[J]. Int J Environ Res Public Health, 2021, 18(20):10731. doi:10.3390/ijerph182010731.

组别	n	身高/cm	体质量/kg	BMI/（kg/m²）	超重/肥胖
非MAFLD新兵	3 254	173.3±5.8	71.5±9.7	23.78±2.68	1 496（46.0）
MAFLD新兵	215	173.5±6.0	81.6±8.6	27.06±2.02	198（92.1）
t或χ²		0.549	14.884^＊	17.673^＊	171.674^＊

组别	n	身高/cm	体质量/kg	BMI/（kg/m²）	超重/肥胖
非MAFLD新兵	3 254	173.3±5.8	71.5±9.7	23.78±2.68	1 496（46.0）
MAFLD新兵	215	173.5±6.0	81.6±8.6	27.06±2.02	198（92.1）
t或χ²		0.549	14.884^＊	17.673^＊	171.674^＊

组别		体质量/kg	BMI/（kg/m²）		腰围/cm		臀围/cm	腰臀比		体脂肪/kg		体脂率/%		FPG/（mmol/L）			ALT/（U/L）	AST/（U/L）
集训前		81.9±8.6	26.90±1.98		82.57±6.04		97.23±4.81	0.85±0.04		21.43±4.18		26.06±3.74		4.94±0.43			35.31±23.43	35.58±28.15
集训后		74.7±7.9	24.56±2.01		78.57±5.78		98.45±4.56	0.80±0.05		15.25±3.34		20.32±3.51		4.51±0.33			18.46±5.74	17.51±2.61
t		19.840^＊	21.047^＊		6.730^＊		3.172^＊	9.240^＊		22.531^＊		23.722^＊		6.085^＊			5.090^＊	4.726^＊
组别	GGT/ （U/L）		Scr/ （μmol/L）	BUN/ （mmol/L）		UA/ （μmol/L）			TC/ （mmol/L）		TG/ （mmol/L）		LDL-C/ （mmol/L）		HDL-C/ （mmol/L）	肝脂肪变测值/（dB/m）			肝硬度/ kPa
集训前	23.98±9.32		77.81±9.53	5.22±0.98		462.2±101.25			3.99±0.81		0.81±0.51		2.54±0.71		1.15±0.22	273.14±42.29			8.04±2.49
集训后	20.66±8.13		80.35±10.05	5.64±0.88		401.5±88.41			4.00±0.67		1.11±0.62		2.64±0.63		1.18±0.23	225.20±34.03			6.58±1.30
t	1.967		1.403	2.308^＊		3.142^＊			0.087		3.239^＊		0.829		0.720	9.090^＊			4.161^＊

组别		体质量/kg	BMI/（kg/m²）		腰围/cm		臀围/cm	腰臀比		体脂肪/kg		体脂率/%		FPG/（mmol/L）			ALT/（U/L）	AST/（U/L）
集训前		81.9±8.6	26.90±1.98		82.57±6.04		97.23±4.81	0.85±0.04		21.43±4.18		26.06±3.74		4.94±0.43			35.31±23.43	35.58±28.15
集训后		74.7±7.9	24.56±2.01		78.57±5.78		98.45±4.56	0.80±0.05		15.25±3.34		20.32±3.51		4.51±0.33			18.46±5.74	17.51±2.61
t		19.840^＊	21.047^＊		6.730^＊		3.172^＊	9.240^＊		22.531^＊		23.722^＊		6.085^＊			5.090^＊	4.726^＊
组别	GGT/ （U/L）		Scr/ （μmol/L）	BUN/ （mmol/L）		UA/ （μmol/L）			TC/ （mmol/L）		TG/ （mmol/L）		LDL-C/ （mmol/L）		HDL-C/ （mmol/L）	肝脂肪变测值/（dB/m）			肝硬度/ kPa
集训前	23.98±9.32		77.81±9.53	5.22±0.98		462.2±101.25			3.99±0.81		0.81±0.51		2.54±0.71		1.15±0.22	273.14±42.29			8.04±2.49
集训后	20.66±8.13		80.35±10.05	5.64±0.88		401.5±88.41			4.00±0.67		1.11±0.62		2.64±0.63		1.18±0.23	225.20±34.03			6.58±1.30
t	1.967		1.403	2.308^＊		3.142^＊			0.087		3.239^＊		0.829		0.720	9.090^＊			4.161^＊

组别	n			体质量/kg											BMI/（kg/m²）										腰围/cm									臀围/cm
组别	n			集训前				集训后				t			集训前			集训后			t				集训前				集训后			t		集训前				集训后				t
正常组	36			82.0±8.8				74.4±7.9				18.513^＊			26.89±1.88			24.40±1.83			19.586^＊				82.61±5.53				78.17±5.90			6.311^＊		97.36±4.81				98.22±4.43				1.713
未好转组	20			81.6±8.4				75.4±8.1				9.618^＊			26.91±2.19			24.86±2.32			10.324^＊				82.50±7.02				79.30±5.62			2.963^＊		97.00±4.92				98.85±4.88				3.285^＊
t				0.165				0.436							0.034			0.821							0.065				0.700					0.267				0.490
组别		腰臀比												体脂肪/kg										体脂率/%											FPG/（mmol/L）
组别		集训前			集训后				t					集训前			集训后			t				集训前				集训后		t					集训前			集训后				t
正常组		0.85±0.04			0.80±0.05				8.047^＊					21.31±4.18			14.69±3.03			20.464^＊				25.87±3.91				19.68±3.38		21.433^＊					4.95±0.49			4.52±0.33				4.572^＊
未好转组		0.85±0.05			0.80±0.04				4.700^＊					21.66±4.28			16.27±3.70			11.702^＊				26.42±3.48				21.47±3.52		12.874^＊					4.92±0.30			4.51±0.35				4.145^＊
t		0.118			0.490									0.301			1.725							0.527				1.866							0.225			0.071
组别	ALT/（U/L）													AST/（U/L）										GGT/（U/L）									Scr/（μmol/L）
组别	集训前						集训后				t			集训前			集训后			t				集训前			集训后				t		集训前						集训后				t
正常组	32.34±11.54						18.16±5.90				6.295^＊			33.49±14.57			17.24±2.30			6.439^＊				24.54±9.60			18.37±4.55				3.602^＊		77.54±9.36						79.21±10.58				0.714
未好转组	40.66±36.00						19.00±5.54				2.587^＊			39.35±43.36			17.99±3.08			2.173^＊				22.96±8.94			24.80±11.18				0.546		78.28±10.06						82.42±8.89				1.418
t	1.282						0.517							0.743			1.038							0.600			3.044^＊						0.274						1.148
组别				BUN/（mmol/L）									UA/（μmol/L）													TC/（mmol/L）							TG/（mmol/L）
组别				集训前			集训后			t			集训前					集训后					t			集训前			集训后	t			集训前			集训后				t
正常组				5.14±1.03			5.67±0.98			2.165^＊			469.72±100.49					397.53±92.09					2.960^＊			4.01±0.77			3.98±0.49	0.211			0.84±0.60			1.00±0.60				1.436
未好转组				5.36±0.90			5.58±0.68			0.860			448.65±103.78					408.75±83.17					1.253			3.94±0.90			4.03±0.92	0.445			0.76±0.28			1.30±0.62				3.677^＊
t				0.813			0.352						0.743					0.452								0.346			0.236				0.603			1.747
组别			LDL-C/（mmol/L）										HDL-C/（mmol/L）									肝脂肪变测值/（dB/m）												肝硬度/kPa
组别			集训前			集训后					t		集训前			集训后			t			集训前					集训后				t			集训前			集训后				t
正常组			2.54±0.67			2.63±0.45					0.665		1.17±0.21			1.18±0.20			0.108			267.92±46.31					218.14±33.04				7.168^＊			7.88±2.80			6.43±1.21				2.954^＊
未好转组			2.55±0.80			2.66±0.88					0.490		1.10±0.23			1.17±0.27			1.019			282.55±32.87					237.90±32.81				5.552^＊			8.32±1.83			6.84±1.45				3.301^＊
t			0.031			0.154							1.261			0.122						1.247					2.150^＊							0.629			1.117